Safety and efficacy of teneligliptin

A novel DPP-4 inhibitor for hemodialysis patients with type 2 diabetes

Hideo Otsuki, Takeo Kosaka, Kenzo Nakamura, Fumihiko Shimomura, Yoshitaka Kuwahara, Takuji Tsukamoto

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Purpose: Teneligliptin is a novel DPP-4 inhibitor in development for treating type 2 diabetes mellitus that does not require dose adjustment for diabetic patients with end-stage renal disease; however, it had not been known whether or not teneligliptin is safe or potent in dialysis patients. We conducted a prospective study to assess the utility of teneligliptin for diabetic patients undergoing hemodialysis. Methods: Blood glucose, glycated albumin, and HbA1c were measured every 4 weeks, at 4, 12, 20, and 28 weeks, and every 8 weeks, respectively, for patients treated with teneligliptin (n = 14; 7 patients newly started and 7 that switched from other medications) and patients of a control group who continued ongoing antidiabetic therapy (n = 29). Results: Blood glucose level showed a 36.7 mg/dl decrease from 4 weeks in the teneligliptin group (p < 0.05). The differences in glycated albumin (at 28 w) and HbA1c (at 24 w) between the teneligliptin group and the control group were -3.1 % (p < 0.05) and -0.57 % (p = 0.057), respectively. These parameters also decreased in patients who switched from voglibose 0.2 mg t.i.d. or vildagliptin 50 mg qd after teneligliptin administration. No case with hypoglycemia was identified. One patient had the dose of a laxative administered for constipation increased; however, no patient ceased teneligliptin due to side effects. Conclusion: Teneligliptin 20 mg is well tolerated, safe, and significantly improves glycemic control in diabetic patients with end-stage renal disease. Teneligliptin 20 mg once daily was considered to be more potent than voglibose 0.2 mg t.i.d. or vildagliptin 50 mg qd.

Original languageEnglish
Pages (from-to)427-432
Number of pages6
JournalInternational Urology and Nephrology
Volume46
Issue number2
DOIs
Publication statusPublished - 2014 Feb

Fingerprint

Type 2 Diabetes Mellitus
Renal Dialysis
Safety
Chronic Kidney Failure
Blood Glucose
3-(4-(4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl)pyrrolidin-2-ylcarbonyl)thiazolidine
Laxatives
Control Groups
Constipation
Hypoglycemia
Hypoglycemic Agents
Dialysis
Prospective Studies

Keywords

  • Diabetes mellitus
  • DPP-4 inhibitor
  • End-stage renal disease
  • Glycated albumin
  • Hemodialysis
  • Teneligliptin

ASJC Scopus subject areas

  • Nephrology
  • Urology

Cite this

Safety and efficacy of teneligliptin : A novel DPP-4 inhibitor for hemodialysis patients with type 2 diabetes. / Otsuki, Hideo; Kosaka, Takeo; Nakamura, Kenzo; Shimomura, Fumihiko; Kuwahara, Yoshitaka; Tsukamoto, Takuji.

In: International Urology and Nephrology, Vol. 46, No. 2, 02.2014, p. 427-432.

Research output: Contribution to journalArticle

Otsuki, Hideo ; Kosaka, Takeo ; Nakamura, Kenzo ; Shimomura, Fumihiko ; Kuwahara, Yoshitaka ; Tsukamoto, Takuji. / Safety and efficacy of teneligliptin : A novel DPP-4 inhibitor for hemodialysis patients with type 2 diabetes. In: International Urology and Nephrology. 2014 ; Vol. 46, No. 2. pp. 427-432.
@article{49b7353f02584599a1197cf3b2a93216,
title = "Safety and efficacy of teneligliptin: A novel DPP-4 inhibitor for hemodialysis patients with type 2 diabetes",
abstract = "Purpose: Teneligliptin is a novel DPP-4 inhibitor in development for treating type 2 diabetes mellitus that does not require dose adjustment for diabetic patients with end-stage renal disease; however, it had not been known whether or not teneligliptin is safe or potent in dialysis patients. We conducted a prospective study to assess the utility of teneligliptin for diabetic patients undergoing hemodialysis. Methods: Blood glucose, glycated albumin, and HbA1c were measured every 4 weeks, at 4, 12, 20, and 28 weeks, and every 8 weeks, respectively, for patients treated with teneligliptin (n = 14; 7 patients newly started and 7 that switched from other medications) and patients of a control group who continued ongoing antidiabetic therapy (n = 29). Results: Blood glucose level showed a 36.7 mg/dl decrease from 4 weeks in the teneligliptin group (p < 0.05). The differences in glycated albumin (at 28 w) and HbA1c (at 24 w) between the teneligliptin group and the control group were -3.1 {\%} (p < 0.05) and -0.57 {\%} (p = 0.057), respectively. These parameters also decreased in patients who switched from voglibose 0.2 mg t.i.d. or vildagliptin 50 mg qd after teneligliptin administration. No case with hypoglycemia was identified. One patient had the dose of a laxative administered for constipation increased; however, no patient ceased teneligliptin due to side effects. Conclusion: Teneligliptin 20 mg is well tolerated, safe, and significantly improves glycemic control in diabetic patients with end-stage renal disease. Teneligliptin 20 mg once daily was considered to be more potent than voglibose 0.2 mg t.i.d. or vildagliptin 50 mg qd.",
keywords = "Diabetes mellitus, DPP-4 inhibitor, End-stage renal disease, Glycated albumin, Hemodialysis, Teneligliptin",
author = "Hideo Otsuki and Takeo Kosaka and Kenzo Nakamura and Fumihiko Shimomura and Yoshitaka Kuwahara and Takuji Tsukamoto",
year = "2014",
month = "2",
doi = "10.1007/s11255-013-0552-6",
language = "English",
volume = "46",
pages = "427--432",
journal = "International Urology and Nephrology",
issn = "0301-1623",
publisher = "Springer Netherlands",
number = "2",

}

TY - JOUR

T1 - Safety and efficacy of teneligliptin

T2 - A novel DPP-4 inhibitor for hemodialysis patients with type 2 diabetes

AU - Otsuki, Hideo

AU - Kosaka, Takeo

AU - Nakamura, Kenzo

AU - Shimomura, Fumihiko

AU - Kuwahara, Yoshitaka

AU - Tsukamoto, Takuji

PY - 2014/2

Y1 - 2014/2

N2 - Purpose: Teneligliptin is a novel DPP-4 inhibitor in development for treating type 2 diabetes mellitus that does not require dose adjustment for diabetic patients with end-stage renal disease; however, it had not been known whether or not teneligliptin is safe or potent in dialysis patients. We conducted a prospective study to assess the utility of teneligliptin for diabetic patients undergoing hemodialysis. Methods: Blood glucose, glycated albumin, and HbA1c were measured every 4 weeks, at 4, 12, 20, and 28 weeks, and every 8 weeks, respectively, for patients treated with teneligliptin (n = 14; 7 patients newly started and 7 that switched from other medications) and patients of a control group who continued ongoing antidiabetic therapy (n = 29). Results: Blood glucose level showed a 36.7 mg/dl decrease from 4 weeks in the teneligliptin group (p < 0.05). The differences in glycated albumin (at 28 w) and HbA1c (at 24 w) between the teneligliptin group and the control group were -3.1 % (p < 0.05) and -0.57 % (p = 0.057), respectively. These parameters also decreased in patients who switched from voglibose 0.2 mg t.i.d. or vildagliptin 50 mg qd after teneligliptin administration. No case with hypoglycemia was identified. One patient had the dose of a laxative administered for constipation increased; however, no patient ceased teneligliptin due to side effects. Conclusion: Teneligliptin 20 mg is well tolerated, safe, and significantly improves glycemic control in diabetic patients with end-stage renal disease. Teneligliptin 20 mg once daily was considered to be more potent than voglibose 0.2 mg t.i.d. or vildagliptin 50 mg qd.

AB - Purpose: Teneligliptin is a novel DPP-4 inhibitor in development for treating type 2 diabetes mellitus that does not require dose adjustment for diabetic patients with end-stage renal disease; however, it had not been known whether or not teneligliptin is safe or potent in dialysis patients. We conducted a prospective study to assess the utility of teneligliptin for diabetic patients undergoing hemodialysis. Methods: Blood glucose, glycated albumin, and HbA1c were measured every 4 weeks, at 4, 12, 20, and 28 weeks, and every 8 weeks, respectively, for patients treated with teneligliptin (n = 14; 7 patients newly started and 7 that switched from other medications) and patients of a control group who continued ongoing antidiabetic therapy (n = 29). Results: Blood glucose level showed a 36.7 mg/dl decrease from 4 weeks in the teneligliptin group (p < 0.05). The differences in glycated albumin (at 28 w) and HbA1c (at 24 w) between the teneligliptin group and the control group were -3.1 % (p < 0.05) and -0.57 % (p = 0.057), respectively. These parameters also decreased in patients who switched from voglibose 0.2 mg t.i.d. or vildagliptin 50 mg qd after teneligliptin administration. No case with hypoglycemia was identified. One patient had the dose of a laxative administered for constipation increased; however, no patient ceased teneligliptin due to side effects. Conclusion: Teneligliptin 20 mg is well tolerated, safe, and significantly improves glycemic control in diabetic patients with end-stage renal disease. Teneligliptin 20 mg once daily was considered to be more potent than voglibose 0.2 mg t.i.d. or vildagliptin 50 mg qd.

KW - Diabetes mellitus

KW - DPP-4 inhibitor

KW - End-stage renal disease

KW - Glycated albumin

KW - Hemodialysis

KW - Teneligliptin

UR - http://www.scopus.com/inward/record.url?scp=84896707203&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896707203&partnerID=8YFLogxK

U2 - 10.1007/s11255-013-0552-6

DO - 10.1007/s11255-013-0552-6

M3 - Article

VL - 46

SP - 427

EP - 432

JO - International Urology and Nephrology

JF - International Urology and Nephrology

SN - 0301-1623

IS - 2

ER -